Approved Research
Association between metabolic dysfunction-associated steatotic liver disease (MASLD) and extrahepatic diseases
Lay summary
Lay summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) has established a new diagnostic standard for fatty liver disease independent of alcohol intake and associated viral hepatitis infection. MASLD is different from the previous nonalcoholic fatty liver disease (NAFLD) and is defined by its own set of inclusion criteria rather than exclusion criteria. NAFLD has a certain correlation with extrahepatic diseases. However, it is not clear whether the newly defined MASLD is related to extrahepatic diseases. Therefore, we plan to explore the relationship between MASLD and extrahepatic diseases using the data of the British Biological Bank, and build a prediction model of related diseases. In addition, we will use the cohort study data of a single center to verify (Registration number!ChiCTR2200058543). This study will be of great significance to the early intervention and treatment of MASLD. More importantly, we are more interested in exploring the burden of disease caused by MAFSLD.
Scope extension: Scientific Questions:
1) Is MASLD associated with long-term extrahepatic and extrahepatic cancer?
2) Is MASLD associated with long-term cardiovascular and cerebrovascular diseases?
3) Is MASLD associated with long-term chronic kidney disease?
4) Is MASLD associated with other long-term systemic diseases?
5) How much of a disease burden does MASLD impose?
Aim:
1) To explore the long-term prognosis of MASLD patients, including cancer incidence rate, cardiovascular events and mortality.
2) To explore the relationship between the incidence rate of different systemic diseases in patients with MASLD with different gene phenotypes.
3) To explore the factors affecting the occurrence of intrahepatic and extrahepatic diseases in patients with MASLD.
4) To build a prediction model for the occurrence of intrahepatic and extrahepatic diseases in patients with MASLD.
5) To measure the burden of disease caused by MASLD.